QP 16 - CNS 4: Brain Mets and LMD

Moderator(s)

• 

  Stuart Burri, MD

  Levine Cancer Institute
  Charlotte, NC
• 

  Stephanie Yoon, MD, MS

  City of Hope National Medical Center
  Duarte, California

Presentations:

• 5:15 PM – 5:20 PM ET

  Introduction
• 5:20 PM – 5:25 PM ET

  Genomic Signature for Leptomeningeal Progression in Brain Metastasis Patients Using Liquid Biopsy-Acquired Comprehensive Genomic Profiling
  

  Presenter: Claire Lanier, MD – Wake Forest School of Medicine
• 5:25 PM – 5:30 PM ET

  Cost-Effectiveness of Proton Craniospinal Irradiation (pCSI) in Patients with Solid Tumor Leptomeningeal Metastasis
  

  Presenter: Anna Dornisch, MD – UC San Diego
• 5:30 PM – 5:35 PM ET

  Characterization of Focal Leptomeningeal Disease among Patients with Brain Metastases: A Novel Entity
  

  Presenter: Nayan Lamba, MD – Harvard Radiation Oncology Program
• 5:35 PM – 5:40 PM ET

  Pre-Operative vs. Post-Operative Fractionated Stereotactic Radiotherapy: A Single-Institution Analysis of 534 Resected Metastases
  

  Presenter: Haley Perlow, MD – Case Western Reserve University/University Hospitals Cleveland Medical Center
• 5:40 PM – 5:45 PM ET

  Maximum Tolerated Dose of Neoadjuvant Stereotactic Radiosurgery and Post-Treatment Immune Profiling for Metastatic Brain Tumors: Results of a Phase I Dose Escalation Trial
  

  Presenter: Samuel Zhang, MD – Cedars-Sinai Medical Center
• 5:45 PM – 5:50 PM ET

  Multi-Center Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases (BM) or Leptomeningeal Metastases (LM) Harboring PI3K Pathway Mutations
  

  Presenter: Brandon Imber, MD, MS – Memorial Sloan Kettering Cancer Center
• 5:50 PM – 6:10 PM ET

  Questions and Answers
• 6:10 PM – 6:15 PM ET

  Closing